Stephen T. Isaacs Sells 40,000 Shares of Aduro BioTech Inc (ADRO) Stock

Aduro BioTech Inc (NASDAQ:ADRO) CEO Stephen T. Isaacs sold 40,000 shares of the business’s stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $12.19, for a total value of $487,600.00. Following the sale, the chief executive officer now directly owns 144,025 shares of the company’s stock, valued at $1,755,664.75. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Stephen T. Isaacs also recently made the following trade(s):

  • On Tuesday, May 16th, Stephen T. Isaacs sold 16,673 shares of Aduro BioTech stock. The stock was sold at an average price of $10.00, for a total value of $166,730.00.
  • On Monday, May 15th, Stephen T. Isaacs sold 10,600 shares of Aduro BioTech stock. The stock was sold at an average price of $10.01, for a total value of $106,106.00.
  • On Tuesday, May 16th, Stephen T. Isaacs sold 27,273 shares of Aduro BioTech stock. The stock was sold at an average price of $10.01, for a total value of $273,002.73.

Shares of Aduro BioTech Inc (ADRO) traded down 1.22% during trading on Wednesday, hitting $12.15. The stock had a trading volume of 354,202 shares. The firm’s market cap is $895.16 million. Aduro BioTech Inc has a 52-week low of $8.75 and a 52-week high of $16.18. The stock has a 50 day moving average of $12.28 and a 200 day moving average of $10.96.

Aduro BioTech (NASDAQ:ADRO) last announced its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.27) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by $0.02. The firm had revenue of $5.90 million for the quarter, compared to the consensus estimate of $3.98 million. Aduro BioTech had a negative net margin of 327.87% and a negative return on equity of 31.97%. Aduro BioTech’s revenue was down 84.9% on a year-over-year basis. During the same period last year, the business earned $0.03 EPS. On average, equities analysts anticipate that Aduro BioTech Inc will post ($1.37) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This article was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://sportsperspectives.com/2017/08/09/stephen-t-isaacs-sells-40000-shares-of-aduro-biotech-inc-adro-stock.html.

ADRO has been the subject of a number of recent research reports. BidaskClub raised Aduro BioTech from a “hold” rating to a “buy” rating in a report on Tuesday, July 25th. HC Wainwright initiated coverage on Aduro BioTech in a report on Monday, May 1st. They set a “buy” rating and a $18.00 price objective for the company. Rodman & Renshaw initiated coverage on Aduro BioTech in a report on Monday, May 1st. They set a “buy” rating and a $18.00 price objective for the company. Zacks Investment Research raised Aduro BioTech from a “hold” rating to a “buy” rating and set a $13.00 price objective for the company in a report on Tuesday, July 4th. Finally, Canaccord Genuity reissued a “buy” rating and set a $30.00 price objective on shares of Aduro BioTech in a report on Wednesday, May 3rd. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company’s stock. Aduro BioTech has a consensus rating of “Buy” and a consensus target price of $19.00.

Several large investors have recently made changes to their positions in ADRO. Legal & General Group Plc increased its stake in shares of Aduro BioTech by 11.2% in the second quarter. Legal & General Group Plc now owns 10,359 shares of the biotechnology company’s stock valued at $118,000 after buying an additional 1,043 shares during the period. Quantitative Systematic Strategies LLC purchased a new stake in shares of Aduro BioTech during the first quarter valued at $145,000. Daiwa SB Investments Ltd. purchased a new stake in shares of Aduro BioTech during the first quarter valued at $153,000. Creative Planning increased its stake in shares of Aduro BioTech by 73.9% in the first quarter. Creative Planning now owns 15,000 shares of the biotechnology company’s stock valued at $161,000 after buying an additional 6,375 shares during the period. Finally, Parametric Portfolio Associates LLC increased its stake in shares of Aduro BioTech by 15.9% in the first quarter. Parametric Portfolio Associates LLC now owns 15,424 shares of the biotechnology company’s stock valued at $166,000 after buying an additional 2,119 shares during the period. 35.60% of the stock is owned by institutional investors.

About Aduro BioTech

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Insider Buying and Selling by Quarter for Aduro BioTech (NASDAQ:ADRO)

Receive News & Ratings for Aduro BioTech Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply